Decision-making on malaria vaccine introduction: The role of cost-effectiveness analyses

Bulletin of the World Health Organization

Volumn 90, Issue 11, 2012, Pages 864-866

  Moorthy, Vasee S ^a   Hutubessy, Raymond ^a   Newman, Robert D ^a   Hombach, Joachim ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; RECOMBINANT VACCINE; RTS,S-AS01 VACCINE;

COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; ENDEMIC DISEASES; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HUMAN; IMMUNOLOGY; INFANT; INNATE IMMUNITY; MALARIA; PHASE 4 CLINICAL TRIAL (TOPIC);

CLINICAL TRIALS, PHASE IV AS TOPIC; COST-BENEFIT ANALYSIS; DECISION MAKING; ENDEMIC DISEASES; EVIDENCE-BASED PRACTICE; HEALTH POLICY; HUMANS; IMMUNITY, INNATE; INFANT; MALARIA; MALARIA VACCINES; VACCINES, SYNTHETIC;

EID: 84868248427     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.12.107482     Document Type: Article

References (14)

1. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011;365:1863-1875. doi:10.1056/NEJMoa1102287 PMID:22007715
2. World Health Organization [Internet]. Malaria. Geneva: WHO; 2012. Available from: http://www.who.int/vaccine_research/Malaria/en/index.html [accessed 12 September 2012].
3. White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions: a systematic review. Malar J 2011;10:337. doi:10.1186/1475-2875-10-337 PMID:22050911
4. Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst Rev 2004;2: CD000363. PMID:15106149
5. Hawley WA, Phillips-Howard PA, ter Kuile FO, Terlouw DJ, Vulule JM, Ombok M et al. Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. Am J Trop Med Hyg 2003;68(Suppl):121-127. PMID:12749495
6. Report on the: WHO Quantitative Immunization and Vaccines Related Research (QUIVER): advisory committee meeting, Geneva, 4-6 October 2011. Geneva: World Health Organization; 2012. Available from: www.whqlibdoc.who.int/hq/2012/WHO_IVB_12.03_eng.pdf [accessed 12 September 2012]
7. Maire N, Shillcutt SD, Walker DG, Tediosi F, Smith TA. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value Health 2011;14:1028-1038. doi:10.1016/j.jval.2011.06.004 PMID:22152171
8. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W et al. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 2010;7: pii: e1000324. doi:10.1371/journal.pmed.1000324 PMID:20711482
9. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009;22:13-36. doi:10.1128/CMR.00025-08 PMID:19136431
10. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006;28:51-60. doi:10.1111/j.1365-3024.2006.00808.x PMID:16438676
11. Hutubessy R, Henao AM, Namgyal P, Moorthy V, Hombach J. Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal. BMC Med 2011;9:55. doi:10.1186/1741-7015-9-55 PMID:21569407
12. Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am J Trop Med Hyg 2006;75:111-118. PMID:16931822
13. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J 2009;8:312. doi:10.1186/1475-2875-8-312 PMID:20042088
14. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010;28:2356-2359. doi:10.1016/j.vaccine.2009.06.035 PMID:19567247